Lange David C, Rokos Ivan C, Garvey J Lee, Larson David M, Henry Timothy D
Division of Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA, USA.
Department of Emergency Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Interv Cardiol Clin. 2016 Oct;5(4):451-469. doi: 10.1016/j.iccl.2016.06.002. Epub 2016 Aug 5.
First-medical-contact-to-device (FMC2D) times have improved over the past decade, as have clinical outcomes for patients presenting with ST-elevation myocardial infarction (STEMI). However, with improvements in FMC2D times, false activation of the cardiac catheterization laboratory (CCL) has become a challenging problem. The authors define false activation as any patient who does not warrant emergent coronary angiography for STEMI. In addition to clinical outcome measures for these patients, STEMI systems should collect data regarding the total number of CCL activations, the total number of emergency coronary angiograms, and the number revascularization procedures performed.
在过去十年中，首次医疗接触至设备（FMC2D）时间有所改善，ST段抬高型心肌梗死（STEMI）患者的临床结局也同样如此。然而，随着FMC2D时间的改善，心脏导管实验室（CCL）的误激活已成为一个具有挑战性的问题。作者将误激活定义为任何不适合因STEMI进行紧急冠状动脉造影的患者。除了这些患者的临床结局指标外，STEMI系统还应收集有关CCL激活总数、紧急冠状动脉造影总数以及进行的血运重建手术数量的数据。
